(Total Views: 648)
Posted On: 09/29/2025 6:10:25 PM
Post# of 157591
* we will use the net proceeds from the sale of the securities offered by this prospectus and the exercise price from the exercise of any convertible securities, if any, for working capital and general
corporate purposes.
Said it many times, the S3 will be for General working capital.
___
*Pending the application of the net proceeds for these purposes, we expect to invest the proceeds in short-term, interest-bearing instruments or other investment-grade securities.
A new investment vehicle to buy into Creativ-bio --- fingers crossed.
___
*As described above, our Board is authorized to designate and issue shares of preferred stock in series and define all rights, preferences and
privileges applicable to such series. This authority may be used to make it more difficult or less economically beneficial to acquire or seek
to acquire us.
Been saying --- Cytodyn is not developing like a company who intends to be bought. Dr. J's Aug video saying --- "we are all in"...combined now with this filing comment says -- We're building a brand.
Including whoever has mentioned poison pill if ever needed, is now also correct.
___
*Unless otherwise set forth in a prospectus supplement accompanying this prospectus, we may sell the securities being offered hereby, from
time to time, by one or more of the following methods:
** to investors directly in negotiated sales or in competitively bid transactions **
After Mr. Hoffman's presentation, I asked/posted --- do you think these HNW individuals are just going to walk-away from addtl data &/or, did not secure 1st Right of Refusals for certain indications ??
This Prospectus is the company positioning to move the science backed data forward.
2020/2021 trials being attached to 2025 & forward.
Good prospectus filing
corporate purposes.
Said it many times, the S3 will be for General working capital.
___
*Pending the application of the net proceeds for these purposes, we expect to invest the proceeds in short-term, interest-bearing instruments or other investment-grade securities.
A new investment vehicle to buy into Creativ-bio --- fingers crossed.
___
*As described above, our Board is authorized to designate and issue shares of preferred stock in series and define all rights, preferences and
privileges applicable to such series. This authority may be used to make it more difficult or less economically beneficial to acquire or seek
to acquire us.
Been saying --- Cytodyn is not developing like a company who intends to be bought. Dr. J's Aug video saying --- "we are all in"...combined now with this filing comment says -- We're building a brand.
Including whoever has mentioned poison pill if ever needed, is now also correct.
___
*Unless otherwise set forth in a prospectus supplement accompanying this prospectus, we may sell the securities being offered hereby, from
time to time, by one or more of the following methods:
** to investors directly in negotiated sales or in competitively bid transactions **
After Mr. Hoffman's presentation, I asked/posted --- do you think these HNW individuals are just going to walk-away from addtl data &/or, did not secure 1st Right of Refusals for certain indications ??
This Prospectus is the company positioning to move the science backed data forward.
2020/2021 trials being attached to 2025 & forward.
Good prospectus filing
(8)
(0)
